PROTEINURIA IS A PROMINENT feature of many renal diseases. It is a consequence of glomerular capillary wall breakdown, causing abnormal transglomerular passage of plasma protein. Excessive plasma proteins can gain access to the proximal tubular cells (PTC), causing tubulointerstitial inflammation, tubular atrophy, and tubulointerstitial fibrosis (2, 41) . The most prevalent protein in the urine of nephritic patients is human serum albumin (HSA). Several authors have postulated that excessive filtration of HSA into proximal tubules may have a detrimental effect on tubulointerstitial function (18, 44) . In in vitro experiments, albumin stimulates various intracellular signaling pathways in PTC and induces them to produce various chemoattractants and proinflammatory and profibrotic cytokines (4, 11, 12, 46, 52) . Some authors have also demonstrated a proapoptotic effect of albumin in cultured PTC (14, 21) . Thus albumin is one of the major mediators of renal tubulointerstitial disease.
HSA is the most abundant plasma protein and serves as a carrier of endogenous and exogenous compounds (39) . In addition, HSA is quite vulnerable to reactive oxygen species (ROS) (9) . In chronic kidney disease (CKD), oxidative stress is increased because there is an imbalance between excessive generation of oxidant compounds and insufficient antioxidant defense mechanisms. This results in the generation of large amounts of ROS, such as O 2 Ϫ , H 2 O 2 , and HOCl, by activation of neutrophils. In particular, HOCl, which is a powerful oxidizing agent, reacts with a wide variety of biological molecules, such as DNA, amino acids, peptides, and proteins (1, 40, 47) . Recently, Witko-Sarsat et al. (48) reported the presence of elevated levels of advanced oxidation protein products (AOPPs) in the plasma of uremia, and Capeillere-Blandin et al. (5) identified albumin as the main AOPPs in plasma. Furthermore, plasma concentration of AOPPs was closely correlated with the levels of dityrosine, a hallmark of oxidized protein, and pentosidine, a marker of protein glycation closely related to oxidative stress (19) . Thus AOPPs might be formed during oxidative stress by the reaction of plasma albumin with chlorinated oxidants and considered novel markers of oxidantmediated protein damage (48) .
A more recent finding is that AOPPs are highly correlated with carotid intima media thickness (13) and may even be related to atherosclerotic cardiovascular events (10) . Chronic administration of AOPPs accelerated atherosclerosis in a hyperlipidemic rabbit model (29) . A clinical study revealed a close relationship between levels of AOPPs and serum markers of monocyte activation (49) . These data suggest that these oxidized proteins contribute to the inflammatory processes associated with several diseases. On the basis of this information, we hypothesized that a large amount of plasma AOPPs may access PTC across the glomerulus and cause PTC injury, such as that caused by HSA. Recently, Li et al. (26) showed that treatment with AOPPs-HSA enhanced AOPPs levels in plasma and renal tissue and upregulated expression of monocyte chemoattractant protein-1 and transforming growth factor (TGF)-␤1 in the renal cortex, demonstrating that chronic accumulation of AOPPs promotes renal fibrosis. However, the underlying mechanisms of induced progressive renal damage by AOPPs at the cellular level remain largely unresolved.
In the present study, chloramine-T (HOCl analog) was used to prepare AOPPs-HSA. Chloramines are primarily produced by HOCl reactions (43) . Because chloramines retain the oxidizing equivalents of HOCl and are longer lived than HOCl (38, 47) , chloramines are one of the important oxidants involved in the progression of CKD. Therefore, we examined the mechanisms of AOPPs-HSA and the detrimental effects induced by AOPPs-HSA in HK-2 cells (in vitro model as PTC).
MATERIALS AND METHODS
Chemicals. HSA was donated by the Chemo-Sera-Therapeutic Research Institute (Kumamoto, Japan). BSA (fraction V) was purchased from Wako Pure Chemical Industries (Osaka, Japan). Chloramine T and protease inhibitor cocktail were purchased from Nacalai Tesque (Kyoto, Japan). Keratinocyte serum-free medium (K-SFM) and epidermal growth factor were purchased from Gibco Life Technologies. Bovine pituitary extract was purchased from Kurabo. DMEM was obtained from Sigma (St. Louis, MO). Penicillin G (1,650 IU/mg), streptomycin sulfate (750 IU/mg), G418, and Ham's F-12 medium were purchased from Life Technologies, and Na 125 I (3.7 GBq/ml in NaOH) was purchased from Amersham Pharmarcia Biotech (Little Chalfont, Buckinghamshire, UK). Goat anti-CD36 polyclonal antibody (L-17), goat anti-actin polyclonal antibody (I-19), and horseradish peroxidase (HRP)-rabbit anti-goat IgG (H ϩ L) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-human CD36 monoclonal antibody (FA6-152) was purchased from Immunotech. Humanized mouse anti-human lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1) monoclonal antibody (JTX92) was donated by Dr. T. Sawamura (National Cardiovascular Center Research Institute, Osaka, Japan). All reagents used were of the highest grade available from commercial sources.
AOPPs-HSA preparation and determination. Fraction V HSA (96% pure) was defatted using the charcoal procedure described by Chen (6), deionized, freeze dried, and then stored at Ϫ20°C until used. AOPPs-HSA was prepared in vitro as described previously (22) . Briefly, HSA (300 M) was incubated for 1 h in phosphate buffer (pH 8.0) at 37°C in an oxygen-saturated solution containing 100 mM chloramine-T, an HOCl analog. After incubation, the oxidation reactions were stopped by extensive dialysis of solutions against water. The control involved incubating HSA dissolved in buffer alone, and in all cases the proteins were stored at Ϫ20°C until use. The endotoxin levels in HSA and AOPPs-HSA were measured with the Limulus Amoebocyte lysate test (the endospecy test) and were found to be below 0.072 ng/mg protein in HSA and 0.095 ng/mg protein in AOPPs-HSA. Since Valencia et al. (45) demonstrated that low levels of endotoxin (below 0.2 ng/mg protein) did not show any effects on the induction of cellular responses, we used those AOPPs-HSA preparations in the present study. The content of AOPPs, which was thought as a useful oxidative stress marker, was determined as described previously (49) . Briefly, 200 l of samples were placed in a 96-well microtiter plate (Becton Dickinson Labware, Lincoln Park, NJ) and mixed with 20 l of acetic acid. In standard wells, 10 l of 1.16 mol/l potassium iodide was added to 200 l of chloramine-T solution, followed by 20 l of acetic acid. The absorbance of the reaction mixture at 340 nm was read immediately in a microplate reader. The contents of AOPPs in our AOPPs-HSA and HSA samples (1.34 mg/ml solutions) were 244.3 Ϯ 12.3 M and 10.3 Ϯ 6.3 M, respectively. Since we used 0.0025-5 mg/ml of AOPPs-HSA or HSA throughout the present study, the ranges of the AOPPs content in AOPPs-HSA and HSA were 0.46 -911.5 M and 0.019 -38.5 M, respectively. Dityrosine content, which is also a useful oxidative stress marker, of AOPPs-HSA was also significantly greater than that of HSA (0.7 Ϯ 0.11 vs. 0.32 Ϯ 0.13 nmol dityrosine per miligram of protein; P Ͻ 0.01). The contents of AOPPs and dityrosine in the plasma of patients undergoing hemodialysis are reported as 267.5 Ϯ 16.5 M and 1.03 Ϯ 0.12 nmol dityrosine per miligram of protein, respectively (48) , thus indicating that the degree of modification of our AOPPs-HSA preparation is comparatively similar to that of AOPPs and dityrosine levels in the plasma of patients undergoing hemodialysis. To determine whether the AOPPs-HSA contained advanced glycation end products (AGE), we measured the content of N ε -(carboxylmethyl)lysine (CML), pyrraline, pentosidine, and imidazolone in both AOPPs-HSA and unmodified HSA by ELISA, as described elsewhere (32) . Briefly, each well of a 96-well microtiter plate was coated with 100 l of the sample to be tested in 50 mM sodium carbonate buffer (pH 9.6). Each well was then blocked with 0.5% gelatin and washed three times with PBS containing 0.05% Tween 20 (washing buffer). The wells were incubated for 1 h with each monoclonal antibody against these AGE structures dissolved in washing buffer. The wells were then washed with washing buffer three times, incubated with an HRP-conjugated antimouse IgG antibody, and finally incubated with 1,2-phenylenediamine dihydrochloride. The reaction was terminated by the addition of 0.1 ml of 1.0 M sulfuric acid, and the absorbance at 492 nm was read on a micro-ELISA plate reader. As a result, there were no significant differences in the content of AGE structures between AOPPs-HSA and unmodified HSA. In addition, agarose gel electrophoresis was performed to examine whether there was unmodified HSA in AOPPs-HSA using the Universal Gel/8 electrophoresis kit (Ciba-Corning, Tokyo, Japan), followed by staining with Coomassie brilliant blue (33) . As a result, the electrophoretic mobility of the AOPPs-HSA toward the anode was higher than that of unmodified HSA, and there was no unmodified HSA in the AOPPs-HSA (data not shown).
Protein labeling with 125 I. AOPPs-HSA and HSA were labeled with 125 I by Iodo-Gen (Pierce), as previously described (35) . A solution containing 10 l of Na 125 I solution and 0.5 mg of proteins in 0.2 ml of 0.1 M sodium phosphate buffer (pH 7.4) in an Iodo-Genadhered test tube was incubated for 30 min at room temperature. Unreacted Na 125 I was removed by adding the solution to a PD-10 column followed by elution with PBS. The 125 I-labeled fractions were combined on the basis of their radioactivity, as determined with a well counter. The specific activities of HSA and AOPPs-HSA were 400 and 350 cpm/ng protein, respectively.
Cell culture of HK-2. The immortalized human PTC line HK-2 (American Type Culture Center, Manassas, VA) was cultured at 37°C in 5% CO2 in K-SFM, supplemented with 5 ng/ml human recombinant epidermal growth factor and 0.05 g/ml bovine pituitary extract. HK-2 cells were seeded to tissue culture flasks (Greiner Bio-One) and further grown to confluence until cellular assay.
Cell culture and isolation of a transfected cell line (CD36-CHO cells and mock-CHO cells).
The cDNA of human CD36 was amplified from a human placenta cDNA library by polymerase chain reaction using the primers as described previously (37) . The amplified human CD36 cDNA was transfected into Chinese hamster ovary (CHO)-K1 cells by the electroporation method. CD36-CHO cells were selected and maintained as described previously (37) .
RNA interference of megalin to HK-2 cells. Human megalin siRNA consisted of three target-specific 20-to 25-nt siRNAs, and the siRNA negative control that contained a scrambled sequence was obtained from Santa Cruz Biotechnology. HK-2 cells, 1 ϫ 10 5 , in log phase were plated into six-well tissue culture plates with normal growth medium 24 h before transfection or when the cells reached 60 -80% confluence. For each transfection well, the siRNA-transfection reagent complexes were overlaid onto the washed cells. Cells were incubated in normal cell culture conditions for 7 h, and then fresh normal growth medium was added to each well to maximize cell growth and prevent potential cytotoxicity. After 24 h of transfection, assays for target gene expression by Western blot were performed using goat anti-human megalin antibody (C19, Santa Cruz Biotechnology).
Cellular assays. Cellular endocytosis experiments were performed at 37°C in a humidified atmosphere of 5% CO2 in air. HK-2 cells were cultured in supplemented K-SFM. Cells (1 ϫ 10 6 ) were seeded in a 24-well plate and cultured for 1 day in 1.0 ml of this medium, which was then replaced by unsupplemented K-SFM (medium A). After culture for 1 h (cells cultured to 90 -100% confluence), each well received 0.5 ml of medium A containing various concentrations of 125 I-HSA or 125 I-AOPPs-HSA in either the presence or the absence of 50-fold excess amounts of the unlabeled ligands. For inhibition experiments, the incubation medium also included anti-human CD36 monoclonal antibody (FA6-152, 80 g/ml) or control IgG (antihuman IgG monoclonal antibody, 80 g/ml). CD36-CHO cells and mock-CHO cells were maintained with Ham's F-12 medium (Gibco) supplemented with 10 g/ml of blasticidin S (Funakoshi, Tokyo, Japan) and 10% fetal calf serum (medium B) in humidified air with 5% CO 2. Cells (1 ϫ 10 6 ) were seeded in a 24-well plate and cultured for 1 day in 1.0 ml of medium B, which was then replaced by DMEM containing 3% BSA (medium C). After being cultured for 1 h, each well received 0.5 ml of medium C containing various concentrations of 125 I-AOPPs-HSA in either the presence or the absence of 50-fold excess amounts of the unlabeled ligand to be tested. After incubation for the indicated times, an aliquot (0.375 ml) of the culture medium was mixed with 0.15 ml of 40% trichloroacetic acid (TCA). To this solution was added 0.1 ml of 0.7 M AgNO 3, followed by centrifugation at 1,500 g for 10 min. The resulting supernatant (0.25 ml) was used to determine TCA-soluble radioactivity, which was taken as an index of cellular degradation, since proteins are endocytosed by the cells and delivered to lysosomes where they are degraded and excreted into the culture medium in a TCA-soluble form. Each well was then washed three times with 1.0 ml ice-cold PBS. The cells were lysed with 1.0 ml of 0.1 N NaOH for 1 h at 37°C to determine the cell-associated radioactivity. Specific cell association or degradation was determined by subtracting the nonspecific values from the totals.
Immunoblotting technique. HK-2 cells were solubilized with 1% Triton X-100/PBS buffer containing 50ϫ protease inhibitor cocktail. These samples (10 g) were run on 10% SDS-polyacrylamide gels, followed by electrophoretic transfer to nitrocellulose membrane. The membranes were exposed to a goat anti-CD36 polyclonal antibody (L-17, Santa Cruz Biotechnology), mouse anti-scavenger receptors class A-I/II (SR-A) monoclonal antibody (SRA-E5), humanized antihuman LOX-1 antibody (JTX92), rabbit anti-scavenger receptor class B type 1 (SR-B1) polyclonal antibody (Novus Biologicals), rabbit anti-human receptor for advanced glycation end products (RAGE) polyclonal antibody (5505), or rabbit anti-human galectin-3 polyclonal antibody and visualized by HRP-conjugated anti-goat, -mouse, -human, or -rabbit IgG antibody using the ECL Western blotting detection reagent (Amersham Biosciences). This membrane was reblotted with goat anti-actin polyclonal antibody (I-19, Santa Cruz Biotechnology) as an internal normal. The molecular sizes of CD36, Statistics. Statistical analyses were performed using the Student's t-test. A probability value of P Ͻ 0.05 was considered to indicate statistical significance. (Fig. 1, A  and B) . In addition, endocytic degradation of 125 I-AOPPs-HSA by HK-2 cells occurred at a higher level than HSA (Fig. 1, C  and D) . These results suggest that AOPPs-HSA undergoes endocytosis at a higher level than does HSA in HK-2 cells. Furthermore, we performed the ligand-binding study of AOPPs-HSA in HK-2 cells. The total binding of 125 I-AOPPs-HSA to these cells at 4°C was inhibited by Ͼ60% by the presence of an excess amount of unlabeled AOPPs-HSA. The specific binding, which was obtained by subtracting nonspecific binding from the total binding, showed a saturation curve for which Scatchard analysis revealed a binding site with an apparent K d of 1.93 g/ml and a maximal binding of 111.2 ng/mg of cell protein (data not shown). These results indicated that HK-2 cells possess a high-affinity binding site for AOPPs-HSA. The recognition site for AOPPs-HSA in HK-2 cells was also examined. The cell association of 125 I-AOPPs-HSA with HK-2 cells was effectively replaced by a 50-fold excess of unlabeled AOPPs-HSA (Ͼ80%, P Ͻ 0.01 vs. control), whereas a 50-fold excess of unlabeled HSA had only a slight effect (Ͻ5%, not significant vs. control) (Fig. 2A) . The endocytic degradation of 125 I-AOPPs-HSA was also inhibited almost completely by the presence of a 50-fold excess of unlabeled AOPPs-HSA (Ͼ80%, P Ͻ 0.01), whereas a 50-fold excess of unlabeled HSA had only a slight effect (Ͻ10%) (data not shown). These results indicated that AOPPs-HSA was endocytosed differently from HSA. Although it has been suggested that the receptors involved in the uptake of HSA are mainly the megalin/cubilin receptor complex (3, 8) , those are unlikely to contribute to the endocytosis of AOPPs-HSA because megalin is negatively charged, thus showing a preferential affinity for positively charged proteins (31) , whereas AOPPs-HSA shows a negative charge. To further elucidate the role of megalin/ cubilin complex in the endocytosis of AOPPs-HSA in HK-2 cells, we evaluated the effect of silencing the megalin gene on the endocytosis of AOPPs-HSA. As a result, although the transfection of megalin siRNA (80 pmol) resulted in more than 99% suppression of megalin protein expression in HK-2 cells, the association of 125 I-AOPPs-HSA did not decrease in these cells (Fig. 2, B and C) . In addition, the endocytic degradation of 125 I-AOPPs-HSA was not also affected by megalin siRNA transfection (data not shown). Li et al. (27) demonstrated that transfection by megalin siRNA (50 pmol) resulted in up to 90% suppression of not only megalin but also cubilin protein and mRNA expression in HK-2 cells, suggesting that cubilin protein and mRNA expression are most probably knocked down in cells transfected with megalin siRNA. Therefore, these data demonstrated the evidence that the megalin-cubulin complex is not associated with the endocytosis of AOPPs-HSA in HK-2 cells.
RESULTS

Interaction of AOPPs
CD36 was involved in the endocytosis of AOPPs-HSA in HK-2 cells. Recently, there have been reports of several types of receptors that bind to modified albumin (20) . However, it is not yet clear which scavenger receptor is involved in the endocytosis of AOPPs-HSA by HK-2 cells. The expression of SR-A, scavenger receptors class B (CD36), LOX-1, SR-B1, RAGE, and galectin-3 was examined using a Western blotting analysis in HK-2 cells. As shown in Fig. 3, CD36 , SR-B1, and galectin-3 were expressed in HK-2 cells, whereas SR-A, LOX-1, and RAGE were poorly expressed in HK cells. Specifically, CD36 is one of important receptors that is involved in the endocytosis of oxidized protein in adipocytes (25) , thus suggesting that CD36 may be involved in the uptake of AOPPs-HSA in HK-2 cells. To elucidate this association, the cellular endocytosis of 125 I-AOPPs-HSA was also examined using CD36-CHO cells (overexpressed CD36 in CHO cells) and mock-CHO cells (in which only the vector was transfected to CHO cells) (Fig. 4) . The specific cell association and degradation of 125 IAOPPs-HSA with CD36-CHO cells exhibited a dose-dependent effect (Fig. 4, A and C) . However, the specific cell association and degradation of 125 I-AOPPs-HSA were not observed in mock-CHO cells (Fig. 4, B and D) . These results demonstrated that AOPPs-HSA served as a ligand for CD36. To examine the involvement of CD36 in endocytosis of AOPPs-HSA in HK-2 cells, neutralizing anti-CD36 monoclonal antibody (FA6-152) was used for the endocytic association and degradation of 125 I-AOPPs-HSA in HK-2 cells (Fig. 5) . Nonspecific association, which was measured with a 50-fold excess of unlabeled AOPPs-HSA (Fig. 2) , was subtracted from each experiment. As shown in Fig. 5 , the receptor-mediated specific cell association and degradation of 125 I-AOPPs-HSA in HK-2 cells was significantly inhibited by addition of anti-CD36 antibody (inhibitory effect of association: 35%, P Ͻ 0.05; inhibitory effect of degradation: 45%, P Ͻ 0.01), whereas nonimmune IgG and excess unlabeled HSA had no effect on this process (Ͻ5%, considered not significant vs. control). These results indicate that some endocytic pathways of AOPPs-HSA in HK-2 cells are mediated by CD36.
AOPPs-HSA enhances the expression of CD36 in HK-2 cells. It has been shown that oxidized LDL (ox-LDL) and AGE proteins, such as CD36 ligands, induce CD36 protein synthesis in macrophages (17, 23) . Therefore, the effects of AOPPs-HSA on CD36 protein expression in HK-2 cells were examined. Exposure of cells to 100 g/ml AOPPs-HSA at 37°C for 24 h, but not exposure to HSA, significantly increased levels of CD36 protein expression in cell lysates (Fig. 6 ). This result suggested that proteinuria, including a large amount of AOPPs-HSA, causes a series of adverse effects in PTC, resulting from upregulation of CD36 expression and increased uptake of AOPPs-HSA.
AOPPs-HSA increased the generation of ROS in HK-2 cells.
To assess whether AOPPs-HSA could also induce oxidative stress like HSA, ROS in HK-2 cells was measured by the CM-H 2 DCFDA method and fluorescence-activated cell-sorter analysis. After addition of HSA or AOPPs-HSA (1.0, 2.5, and 5.0 mg/ml) to HK-2 cells, ROS was generated in a dosedependent manner by AOPPs-HSA. To a lesser extent, HSA also generated ROS in HK-2 cells (Fig. 7) . To examine the mechanism of ROS generation by AOPPs-HSA, the authors examined the effects of the following: NAC (20 mM), a ROS scavenger; DPI (10 M), an inhibitor of membrane NADPH oxidase; and staurosporine (100 nM), a PKC inhibitor for ROS generation. As shown in Fig. 7 , all three inhibitors were able to block ROS generation induced by AOPPs-HSA, suggesting that AOPPs-HSA produced intercellular ROS by the activation of PKC and membrane NADPH oxidase. Fig. 5 . Effect of anti-CD36 antibody (FA6-152) on the endocytic uptake of 125 I-AOPPs-HSA by HK-2 cells. Cells were incubated at 37°C for 24 h with 0.5 ml of K-SFM containing 2.5 g/ml of 125 I-AOPPs-HSA in the presence or absence of unlabeled AOPPs-HSA (125 g/ ml), anti-CD36 antibody (FA6-152, 80 g/ml), control antibody (MOPC21, 80 g/ml), or HSA (125 g/ml). Results are the means Ϯ SD (n ϭ 3). *P Ͻ 0.05, **P Ͻ 0.01 vs. control. Fig. 6 . Expression of CD36 induced by AOPPs-HSA in HK-2 cells. Cell proteins (10 g) were subjected to immunoblot analysis using anti-CD36 polyclonal antibody (L-17) (1:100) or anti-␤-actin polyclonal antibody (1:500). Results are the means Ϯ SD (n ϭ 3). *P Ͻ 0.05, **P Ͻ 0.01 vs. control cells.
AOPPs-HSA activated secretion of TGF-␤1 by the CD36 pathway in HK-2 cells.
To confirm whether AOPPs-HSA actually causes injury of HK-2 cells via the CD36 pathway, the secretion of TGF-␤1 proteins, which causes fibrosis on PTC, was examined using an enzyme immunoassay. After the incubation of HK-2 cells with 100 g/ml of HSA or AOPPs-HSA for 24 h, TGF-␤1 proteins in the medium were measured. Higher levels of TGF-␤1 proteins were secreted in the medium by cells exposed to AOPPs-HSA. To a lesser extent, HSA also produced TGF-␤1 (Fig. 8) . The involvement of CD36 in the secretion of TGF-␤1 by AOPPs-HSA was also examined, using an anti-CD36 monoclonal antibody (FA6-152). As expected, FA6-152 significantly inhibited secretion of TGF-␤1 induced by AOPPs-HSA in HK-2 cells. In addition, we examined whether NAC and DPI could suppress the secretion of TGF-␤1 induced by AOPPs-HSA. These inhibitors significantly inhibited the secretion of TGF-␤1 induced by AOPPs-HSA, thus suggesting that ROS generated by AOPPs-HSA act as signaling molecules in HK-2 cells and lead to the activation of TGF-␤1.
DISCUSSION
CKD is a worldwide health problem, and the number of patients with CKD is increasing rapidly (7) . Progressive renal disease is caused by the development of glomerulosclerosis and interstitial fibrosis. Therefore, it is important to explore the factor(s) that promote the process to develop new strategies for suppressing CKD. Recent studies have found that plasma concentration of AOPPs significantly increased with the progression of renal dysfunction in patients (48) and that AOPPs may contribute to the progression of CKD (26) . However, the mechanisms by which AOPP accelerates renal fibrosis remain poorly understood. Therefore, we examined the mechanisms of AOPPs and the detrimental effects induced by AOPPs in HK-2 cells. Taking this approach, the novel findings of the present study were as follows. 1) AOPPs-HSA undergoes endocytic uptake and subsequent lysosomal degradation by PTC and HK-2 cells. 2) These processes were effectively inhibited by anti-CD36 antibody. 3) AOPPs-HSA upregulated the generation of intracellular ROS via a mechanism that involves PKC and membrane NADPH oxidase signaling pathways, and the secretion of TGF-␤1 in HK-2 cells. 4) AOPPs-HSA-induced secretion of TGF-␤1 is mediated by CD36. Thus this study provides new evidence for a detailed mechanism by which AOPPs cause PTC injury via CD36.
CD36 is an 88-kDa transmembrane glycoprotein of the class B scavenger receptor family, and is involved in multiple biological processes (15) . It is broadly expressed by renal tubular cells, platelets, monocytes, adipocytes, endothelial cells, erythroblasts, epithelial cells, and several tumor cell lines (15, 50) . In addition, CD36 interacts with multiple extracellular ligands, including thrombospondin-1, long-chain free fatty acids, modified (oxidized) ox-LDL, collagens I and IV, and AGE (15) . Previous reports showed that the expression of CD36 is upregulated by its own ligand. For instance, Iwashima et al. (23) showed that AGE induced the expression of CD36 in human monocyte-derived macrophages and in THP-1 cells (23). Susztak et al. (42) reported that CD36 expression was induced by D-glucose in PTC. In this study, AOPPs-HSA, a ligand for CD36, significantly induced protein expression of CD36 in a dose-dependent manner. Interestingly, HSA (100 g/ml), not a ligand for CD36, slightly increased the expression of CD36 in HK-2 cells in this study. Recently, Yang et al. showed that high concentrations of normal albumin (1.0 and 10 mg/ml) induced the expression of CD36 in LLC-PK1 cells and enhanced the secretion of bioactive TGF-␤1 and fibronectin with the upregulation of CD36 (50) . Thus this report speculates that high concentrations of HSA (Ͼ1.0 mg/ml) may increase the expression of CD36 in HK-2 cells. These findings suggested the possibility that CD36 may be an important receptor in proximal tubular injury and that AOPPs and normal albumin may be deleterious mediators in this disease.
Recent evidence has clearly shown rapid and significant increases in intracellular ROS after growth factor and cytokine stimulation. These types of ROS appear to be essential for a host of downstream signaling events, including cell proliferation, apoptosis, and fibrosis, and thus contribute to the development of disease (16) . Nakajima et al. (34) reported that albumin upregulated ROS production in PTC and that this was mediated by NADPH oxidase and PKC, indicating that albumin has the ability to increase the generation of ROS in PTC. In the present study, we used 1-5 mg/ml of HSA or AOPPs-HSA to investigate ROS production. The content of AOPPs in the plasma of patients undergoing hemodialysis is reported to be 267.5 M (48), and the AOPPs content in 5 mg/ml AOPPs-HSA used in the present study is 911.5 M, thus indicating that we used a 3.4-fold higher concentration of AOPPs protein than the pathophysiological concentration. We performed these experiments with short-term incubation in such a comparatively high concentration of AOPPs-HSA because AOPPs is continuously generated in vivo. The results of the present study clearly showed that AOPPs-HSA also upregulated increases of intracellular ROS in a dose-dependent manner, and, in particular, 5 mg/ml AOPPs-HSA induced increases in intracellular ROS about 1.8 times higher than did the control. In contrast, 5 mg/ml HSA slightly elevated intracellular ROS, about 1.3 times higher than did the control. A previous report showed that 30 mg/ml HSA significantly induced intracellular ROS about 1.8 times higher than did the control (34) . These results demonstrated that AOPPs-HSA potentially activated the generation of ROS as well as HSA. Interestingly, the increases in ROS induced by AOPPs-HSA were significantly decreased by inhibitors of NADPH oxidase and PKC. It is highly possible that interaction of CD36 and AOPPs-HSA results in increased production of intracellular ROS that may take place via a mechanism that involves NADPH oxidase and PKC.
Since anti-CD36 antibody only partially suppresses the uptake of AOPPs-HSA by HK-2 cells, other receptors in PTC may also be involved in the uptake of AOPPs-HSA. In this study, SR-B1 and galectin-3 were also expressed in HK-2 cells (Fig. 3) , thus suggesting that those are likely to be involved in the endocytosis of AOPPs-HSA in HK-2 cells. Recently, Marsche et al. (30) reported that CHO cells overexpressing class B scavenger receptors such as CD36 and SR-B1 recognize HOCl-modified LDL. SR-B1 also has a multiligand specificity for various forms of native and modified (lipo)proteins (24) , and the protein expression of SR-B1 has been observed in PTC (51) . Therefore, SR-B1 may also be involved in the uptake of AOPPs-HSA in the PTC. In addition, Nishiyama et al. (36) reported that galectin-3, a multifunctional ␤-galactoside-binding lectin, is expressed by epithelial cells of the kidney and participates in development, oncogenesis, cell-to-cell attachment, and inflammation, suggesting that galectin-3 may also play an important role in acute tubular injury. Furthermore, galectin-3 was identified as a component of the AGE receptor complex (28) . These observations suggested that SR-B1 and galectin-3 might also be involved in PTC injury. Although further studies using CHO cells overexpressing SR-B1 and galectin-3 and those neutralizing antibodies would be required to determine whether SR-B1 and galectin-3 are also involved in the proximal tubular injury by AOPPs, there are no reports using the optimal neutralizing antibodies against SR-B1 and galectin-3, thus suggesting that we have to conduct another approach such as the silencing strategies for SR-B1 and galectin-3. However, there is only commercial reagent for SR-B1 knockdown, not for galectin-3. Therefore, for the time being, we performed the transfection of SR-B1 siRNA to HK-2 cells. As a result, although transfection by SR-B1 siRNA (80 pmol) resulted in more than 60% suppression of SR-B1 protein expression in HK-2 cells, the endocytic association and degradation of 125 I-AOPPs-HSA did not decrease in these cells (data not shown). This result directly demonstrated that SR-B1 is not involved in the endocytosis of AOPPs-HSA in HK-2 cells. Further studies using siRNA knockdown against galectin-3 in HK-2 cells would therefore shed some light on the mechanisms of renal tubular injury as well as the extent of the contribution of each factor identified in this study.
In conclusion, a new functional role of CD36 was identified as an essential mediator of tubulointerstitial diseases induced by AOPPs in PTC. Furthermore, because AOPPs-HSA by itself stimulates CD36 expression in human PTC, it is speculated that uptake of AOPPs-HSA by PTC would be increased, causing further progression of renal disease. Therefore, CD36 appears to be closely associated with renal tubular dysfunction. Modulating the expression of CD36 or blocking this receptor may be a good approach in the treatment of renal tubular fibrosis.
